Vorapaxar + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Atherosclerosis

Conditions

Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident, Peripheral Arterial Disease

Trial Timeline

Sep 1, 2007 → Dec 1, 2011

NCT ID

NCT00526474

About Vorapaxar + Placebo

Vorapaxar + Placebo is a phase 3 stage product being developed by Merck for Atherosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00526474. Target conditions include Atherosclerosis, Ischemia, Myocardial Infarction.

What happened to similar drugs?

9 of 20 similar drugs in Atherosclerosis were approved

Approved (9) Terminated (4) Active (9)

🔄Orforglipron + PlaceboEli LillyPhase 3

🔄Olmesartan medoxomil + PlaceboDaiichi SankyoPhase 3

🔄Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPhase 3

✅Rosuvastatin + placebo + aspirin + placeboAstraZenecaApproved

✅Rosuvastatin + PlaceboAstraZenecaApproved

🔄Rosuvastatin + AtorvastatinAstraZenecaPhase 3

🔄Rosuvastatin + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02394730	Phase 1/2	Completed	Sep 1, 2015	Jan 1, 2018	HIV
NCT00527943	Phase 3	Terminated	Dec 1, 2007	Jul 1, 2011	Atherosclerosis
NCT00526474	Phase 3	Completed	Sep 1, 2007	Dec 1, 2011	Atherosclerosis

Competing Products

20 competing products in Atherosclerosis

See all competitors

Product	Company	Stage	Hype Score
Orforglipron + Placebo	Eli Lilly	Phase 3	47
Olmesartan medoxomil + Placebo	Daiichi Sankyo	Phase 3	40
Pactimibe sulfate	Daiichi Sankyo	Phase 2/3	30
Pactimibe	Daiichi Sankyo	Phase 2	35
Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin	Daiichi Sankyo	Phase 3	47
Micronized 17B-estradiol	Johnson & Johnson	Phase 2/3	38
Rosuvastatin + placebo + aspirin + placebo	AstraZeneca	Approved	43
Rosuvastatin + Placebo	AstraZeneca	Approved	35
rosuvastatin + placebo	AstraZeneca	Phase 1	29
Rosuvastatin + Placebo	AstraZeneca	Phase 1	29
Rosuvastatin + Atorvastatin	AstraZeneca	Phase 3	40
Rosuvastatin + Placebo	AstraZeneca	Phase 3	40
Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mg	AstraZeneca	Approved	39
Vorapaxar + Placebo + Aspirin + Clopidogrel	Merck	Phase 2	35
Niacin/simvastatin compared to simvastatin alone at 2 doses	Merck	Approved	43
lovastatin	Merck	Phase 2/3	38
Ezetimibe + Placebo	Merck	Approved	43
Vorapaxar + Placebo	Merck	Phase 3	32
Niaspan	Merck	Pre-clinical	22
MK0633	Merck	Phase 2	35